FAAH Inhibitors in the Limelight, but Regrettably

Overview

Journal Int J Clin Pharmacol Ther

Specialty Pharmacology

Date 2016 May 19

PMID 27191771

Citations 27

Authors

Christophe Mallet

Claude Dubray

Christian Duale

Affiliations

Soon will be listed here.

Abstract

This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.

Citing Articles

Analgesia and peripheral c-fiber modulation by selective Na v 1.8 inhibition in rhesus.

Vardigan J, Pall P, McDevitt D, Huang C, Clements M, Li Y Pain. 2024; 166(3):631-643.

PMID: 39382325 PMC: 11808707. DOI: 10.1097/j.pain.0000000000003404.

Anandamide-Mediated Modulation of Nociceptive Transmission at the Spinal Cord Level.

Spicarova D, Palecek J Physiol Res. 2024; 73(S1):S435-S448.

PMID: 38957948 PMC: 11412359. DOI: 10.33549/physiolres.935371.

Targeting Fatty Acid Amide Hydrolase Counteracts the Epithelial-to-Mesenchymal Transition in Keratinocyte-Derived Tumors.

Kovacs D, Flori E, Bastonini E, Mosca S, Migliano E, Cota C Int J Mol Sci. 2023; 24(24).

PMID: 38139209 PMC: 10743516. DOI: 10.3390/ijms242417379.

Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway.

Hao J, Chen Q, Feng Y, Jiang Q, Sun H, Deng B Cell Death Dis. 2023; 14(4):247.

PMID: 37024452 PMC: 10079857. DOI: 10.1038/s41419-023-05779-z.

Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery.

Dasram M, Walker R, Khamanga S Int J Mol Sci. 2022; 23(21).

PMID: 36362014 PMC: 9658826. DOI: 10.3390/ijms232113223.

References

Martin-Sanchez E, Furukawa T, Taylor J, Martin J . Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009; 10(8):1353-68. DOI: 10.1111/j.1526-4637.2009.00703.x. View

Cravatt B, Demarest K, Patricelli M, Bracey M, Giang D, Martin B . Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98(16):9371-6. PMC: 55427. DOI: 10.1073/pnas.161191698. View

Lichtman A, Shelton C, Advani T, Cravatt B . Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. 2004; 109(3):319-327. DOI: 10.1016/j.pain.2004.01.022. View

Ahn K, Smith S, Liimatta M, Beidler D, Sadagopan N, Dudley D . Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther. 2011; 338(1):114-24. PMC: 3126636. DOI: 10.1124/jpet.111.180257. View

Lichtman A, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D . Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther. 2004; 311(2):441-8. DOI: 10.1124/jpet.104.069401. View

Huggins J, Smart T, Langman S, Taylor L, Young T . An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis.... Pain. 2012; 153(9):1837-1846. DOI: 10.1016/j.pain.2012.04.020. View

Fowler C . The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs--A practical view. Eur Neuropsychopharmacol. 2015; 25(6):749-62. DOI: 10.1016/j.euroneuro.2015.02.005. View

Huitron-Resendiz S, Sanchez-Alavez M, Wills D, Cravatt B, Henriksen S . Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. Sleep. 2004; 27(5):857-65. DOI: 10.1093/sleep/27.5.857. View

Chang L, Luo L, Palmer J, Sutton S, Wilson S, Barbier A . Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol. 2006; 148(1):102-13. PMC: 1617043. DOI: 10.1038/sj.bjp.0706699. View

10.

Maccarrone M, Bab I, Biro T, Cabral G, Dey S, Di Marzo V . Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015; 36(5):277-96. PMC: 4420685. DOI: 10.1016/j.tips.2015.02.008. View

11.

Pertwee R . Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc. 2013; 73(1):96-105. DOI: 10.1017/S0029665113003649. View

12.

Ahn K, McKinney M, Cravatt B . Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev. 2008; 108(5):1687-707. PMC: 3150828. DOI: 10.1021/cr0782067. View

13.

Battista N, Di Tommaso M, Bari M, Maccarrone M . The endocannabinoid system: an overview. Front Behav Neurosci. 2012; 6:9. PMC: 3303140. DOI: 10.3389/fnbeh.2012.00009. View

14.

Li G, Winter H, Arends R, Jay G, Le V, Young T . Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol. 2011; 73(5):706-16. PMC: 3403198. DOI: 10.1111/j.1365-2125.2011.04137.x. View

15.

Cravatt B, Giang D, Mayfield S, Boger D, Lerner R, Gilula N . Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996; 384(6604):83-7. DOI: 10.1038/384083a0. View

16.

Mazier W, Saucisse N, Gatta-Cherifi B, Cota D . The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease. Trends Endocrinol Metab. 2015; 26(10):524-537. DOI: 10.1016/j.tem.2015.07.007. View

17.

Rice A . Should cannabinoids be used as analgesics for neuropathic pain?. Nat Clin Pract Neurol. 2008; 4(12):654-5. DOI: 10.1038/ncpneuro0949. View